PHAGE Corporation

Patients and caregivers have the opportunity to be shared decision makers throughout their patient journeys. With the ability to match health literacy, market access to treatments, and documenting patient outcomes patients can be true stakeholders and knowledgeable healthcare consumers. Our primary use case is in solid tumors and driving patients towards immunotherapies.

PHAGE Corporation is seeking to spin off its exclusive IP assets into Aligned Therapeutics.
Our IP assets will allow us to repurpose drugs using Real-World Data (RWD) with a digital
diagnostic engagement to provide patient support to navigate & access diagnostics,
treatments, and transition of care. In our first milestone, we are seeking to raise $650,000 to
incorporate and launch contracts in one regional market in the US.

Exclusive in-license agreement for the use of Prochlorperazine (PCZ) & Clinical tests IP from
UniQuest. Our digital health application is patient & caregiver facing to drive patient
engagement with the program generating valuable real-world data to support value-based
care contracts with US payers to support off target effects of PCZ increasing bioavailability of
immunotherapy targets.

In 2017, mAb market was at $20 billion, of which 17% are ADCC mAbs. Current projected
CAGR at 23.4% by 2026 (Deloitte) such as ADCC mAb, focused particularly on
Trastuzumab & Cetuximab as payers are transitioning to Value-Based Contracts.

Currently, ~70% of patients treated with monoclonal Antibodies (mAbs) fail treatment
• High cost (US$100,000-150,000 per patient)
• mAbs primarily used as last line treatment
• ~85% of Head & Neck cancer patients are considered non-responders
• Patients have difficulties being shared decision-makers with their treatment plan

Our platform provides to patients and caregivers first a digital engagement tools which
equip users to be shared decision makers during the patient journey. We then provide a
prognostic test to validate who would receive benefit from use of our clinical product with
the initial use case of Prochlorperazine (PCZ) which has an off-target effect to drive better
outcomes in solid tumors. We anticipate using the same platform for other diseases such
as blood cancer and rare disease.

Other pharmacy benefit managers exist in the market but the focus on a specific disease indication tied to a novel mechanism of action we are producing research for differentiates from classic PBM structures.

Working with US Payers through Valued-Based Care contracts, we have the opportunity to
receive a capitated payout per patient. This is a unique opportunity that is afforded by
repurposing clinical assets for oncology indications.

Exclusive in-license agreement for the use of Prochlorperazine (PCZ) & Clinical tests IP from
UniQuest. Our digital health application is patient & caregiver facing to drive patient
engagement with the program generating valuable real-world data to support value-based
care contracts with US payers to support off target effects of PCZ increasing bioavailability of
immunotherapy targets.

Costs would be tied to value based care contracts set up in the US healthcare payer system tying revenue to patient outcomes deriving roughly $3k-$14k dependent on patient outcomes.

Multi sided user model with patients and caregivers as the users and payers as the customer with providers acting as prescribers for the adjuvant treatment and diagnostics. The model is similar to a pharmacy benefit manager with the differentiation of owning IP and supporting the off label usage of the adjuvant treatment products.

Milestone 1 markers for end of year one to set up companion diagnostics program, value based care contracting, and patient healthcare navigator to support tracking their patient journey.

We are raising a series A of $4.81m for 35% valuation of our organization. We are accepting a Seed raise of $685m to sequester 1 contracting region of the USA with our solution.

Value based care contracts share risk among patients, providers, payers, and our organizations. Success is driven by patient engagement and adherence and with that component solved by our digital health platform we can support the patient journey to increase adherence rate for end users.

Not applicable.

Won 4 hackathons in 2020, presentations in 5 global conferences, and validation from Big Pharma partners in hematology and oncology.

Exclusive in-license agreement for the use of Prochlorperazine (PCZ) & Clinical tests IP from
UniQuest. Our digital health application is patient & caregiver facing to drive patient
engagement with the program generating valuable real-world data to support value-based
care contracts with US payers to support off target effects of PCZ increasing bioavailability of
immunotherapy targets.